ADAMTS13 and hepatocellular carcinoma: More recently, Takaya et al. proposed to use the ratio between ADAMTS13 activity and its substrate the von Willebrand factor as a biomarker either for the response to sorafenib treatment [81] or early diagnosis of HCC [82].